Media OutReach
Bora Delivers Highest Operating Cash Flow Margin Since 2020, Enabling 2026 Bolt-On Investments from a Larger, Stronger Platform
Board Proposed NT$10 Cash Dividend Per Share
HONG KONG SAR – Media OutReach Newswire – 11 March 2026 – Bora Pharmaceuticals (“Bora”; TWSE: 6472; OTCQX: BORAY) today announced its financial results and operational highlights for full year 2025 and provides 2026 outlook.
FY25 Business and Financial Highlights
- Company reported full year revenues, with discontinued operations reported separately, of NT$19,014 million, up 9.11% from the prior year and basic EPS of NT$23.90, or NT$2.63 for the fourth quarter. Full year EPS represents a 24.22% year-over-year decline, mostly due to a net loss per share of NT$11.24 from discontinued operations.
- In the fourth quarter, following the completion of tech transfer of production transitions out of the Plymouth area in Minnesota, the COGS of those originally Plymouth-made inventories have been reconsolidated to COGS line. Hence on a like-for-like basis when compared with other quarters in 2025, fourth quarter gross margin would have been approximately 38-39%. The reported high single-digit percentage sequential decline in gross margin, which also led to softened operational leverage, was primarily attributable to a temporary slowdown in DLS orders from following the entry of a new competitor in Nov. with limited launch visibility during the quarter. Higher effective tax rates during the quarter were a direct result of less sell-through downstream from related party transactions of the internally manufactured generic products. In addition, heightened generics competition of Topiramate ER, a leading generics product of Upsher-Smith, was also a negative gross margin mover.
- Management believes the 4Q25 OPEX profile more accurately reflects the expanded operating platform and our strategic repositioning into new focus areas. Sales and marketing expenses increased seasonally in line with market share cadence and channel expansion initiatives, while R&D spending sat on the disciplined side. Gross margin expansion serves as the key lever for operating leverage as scale improves fixed-cost absorption.
- Pharma sales revenue remained volatile in the fourth quarter as legacy inventory phased out and new product approvals remain pending. Generics portfolio competitiveness remains a key focus area in the near term for both top line and gross margin. Nevertheless, led by vigabatrin franchise, Bora’s rare disease portfolio continued to gain impressive market share across dosage forms. The Company aims to actively refill pipelines in 2026 to regain profitable growth.
- The Group’s CDMO business delivered another strong quarter in both revenues and gross margin. Supported by expanded capacity and the addition of new dosage forms, CDMO revenues grew 53.8% year-over-year in 2025 to NT$10.64 billion, including internal orders. Excluding internal orders, revenues reached NT$7.50 billion, representing a 19.53% increase compared to 2024.
- As 2025 marked a year of post-merger integration and strategic consolidation, Bora achieved its highest operating cash flow margin in recent years at 34.74% in the fourth quarter, compared with -4.00% in the same period last year. This improvement reflects the transformation of the Bora Group into a more efficient organization operating on a larger and stronger platform. The Board has proposed a NT$10 cash dividend per share, demonstrating confidence in the Group’s strengthened cash generation and commitment to delivering sustainable returns to shareholders, reaching the highest yield rate proposed.
- Share capital increased 3.18% during the quarter from employee stock option exercise and convertible bond conversions.
Mr. Bobby Sheng, Chairman of Bora Group, stated, “2025 represented a pivotal year for Bora Group. Beyond post-acquisition integration, it was a year of disciplined capital allocation and balance sheet stewardship. Having stepped onto a larger growth platform, we deliberately reassessed optimal cash deployment, portfolio mix of both CDMO and Pharma Sales businesses and forthcoming return metrics under a stable equity structure. One year after closing the 2024 acquisitions, we achieved our highest operating cash flow margin, marking a complete turnaround from the same period last year when the Group first transitioned to its current scale.
The external environment was marked by significant shifts. We operated against a backdrop of renewed U.S. trade and industrial policy shifts, triggering supply chain realignment and foreign exchange fluctuations. At the same time, rapid AI adoption began reshaping manufacturing competitive dynamics, if not capital market funding flow. Concurrently, the Group faced competition in a handful core generic products that remain meaningful contributors to revenue and EBITDA. Discontinued operations aside, based on the reclassified financial statements for 2025 and 2024, EBITDA for continued operations declined 19.0% compared to 2024, but remains 12.5% higher than 2023, underscoring the structurally higher revenues and earnings base established over the past 2 years.
Despite these headwinds, the Group remained profitable and has preserved financial flexibility. Notably, we funded Bora’s largest CDMO CAPEX program in our history and executed the business transformation of Upsher-Smith entirely within existing credit facilities, without incremental equity dilution. While value expansion of this new Bora Group platform took longer than the Company expected, we believe the year demonstrates the resilience of our operating model, disciplined financial management, and our ability to execute strategic investments while maintaining earnings and balance sheet integrity.
We are especially delighted to share the contract renewal with GSK earlier this year. From day one, this partnership was built on mutual trust and a shared commitment to quality. With the latest developments, we are looking at a decade of collaboration with GSK and committing through 2030 speaks to our shared focus on value and reliability. We have also established new partnerships with several high-growth pharmaceuticals over the past few months, further expanding our client base across our North American network. These partners share our belief in an integrated and orchestrated supply chain model, leveraging our multi-site platform to support development, manufacturing, and commercialization needs.
To sum up, the CDMO rolling 12-month external order backlog, after a good quarter of digestion and less working days, arrived at US$264 million. Total external wins in 2025 reached a phenomenal US$482 million, of which 89% were commercial-stage orders and 16 molecules in pre-commercial stage, providing solid visibility into 2026 and beyond especially for Canada and Baltimore sites. At the same time, Bora continues to leverage a unified CDMO network to enhance cost competitiveness for our very own Upsher-Smith generics portfolio.
On the pharma sales side, Upsher-Smith today represents a structurally repositioned platform. Performance has been increasingly driven by lifecycle management, including continued maximization of the infantile spasm franchise, alongside active pipeline replenishment with a heightened focus on differentiated assets, particularly NCEs in rare diseases. Within Generics, we have confirmed 7 launches in 2026, including the recently approved Cyclosporine and an in-licensed product indicated for hyponatremia. We are also observing a more constructive environment for DLS than initially anticipated, with 2026 year-to-date market share maintained. Last but not least, based on our current knowledge of the relevant U.S. patent rulings, if TWi receives approval for Cladribine (gMavenclad), Upsher-Smith, as the exclusive distributor, would be positioned to launch the product in the U.S., subject to customary regulatory and commercial considerations.
Beyond our base expectation of launching more than 10 generic products annually, we have identified revenue and EBITDA accretive, bolt-on investment opportunities to further strengthen this business in 2026. These include progressively expanding our injectable and 505(b)(2) portfolios to enhance differentiation and economics, as well as deepening penetration across proprietary and specialty distribution channels. When we exit this year with a more diversified and better-calibrated product mix, we expect improved earnings resilience and more stable growth trajectory going forward.”
FY25 Operational Achievements & 2026 Outlook
Global CDMO Operations
Global CDMO operations revenue reached record highs for both the quarter and the full year, accounting for approximately 45.78% of reported revenues in the quarter and 39.43% for FY2025. In total, 2.5 billion doses were developed and manufactured. Revenue contribution from the top 20 global pharmaceutical companies declined slightly to 29% from the low-30% range previously, primarily reflecting the addition of several fast-growing pharmaceutical clients to the Company’s portfolio in recent years, with increasing contributions from their successful product launches.
As the Company continues to expand its CDMO capacity and capabilities, including approximately 10% additional aseptic fill/finish capacity and a net ~3% expansion in solid and liquid dosage capacity, Bora Group monitors utilization rate carefully across facilities. While the Company remains confident that investing in U.S. manufacturing capacity is strategically sound, given the importance of the U.S. pharmaceutical market and supply chain resilience, capital allocation must also align with prevailing industry investment cycles. Against this backdrop, a structural supply gap in single-use drug substance (DS) bioreactor capacity, projected to grow at an estimated 8–10% CAGR, reinforces the rationale for continued investment in Tanvex Biopharma (branded as Bora Biologics) as Bora Group expands its CDMO platform. Supported by a more favorable funding environment for early-stage biotech companies in the US, rapidly growing biologics pipeline, increasing FDA approvals, long product lifecycles, and Tanvex’s integrated access to Bora’ Group’s drug product (DP) fill/finish capabilities, the strategic platform presents a compelling long-term value creation opportunity. While this represents a near-term drag on reported earnings, the Company believes these investments are necessary to position Bora Group for long-term participation in the CDMO market that values quality and OTIF (On Time, In Full) delivery.
Pharma Sales Operations
Pharma Sales operations generated revenue of NT$2.64 billion in the fourth quarter, marking one of slowest quarters since the Upsher-Smith merger. For the full year, Pharma Sales declined 11.30% compared to 2024, excluding the impact of discontinued operations related to delisted products, and accounted for 60.48% of total revenues.
A key leading indicator in specialty pharma is the number of new patients, and across the Vigabatrin franchise, Upsher-Smith continues to demonstrate positive momentum on this front. Upsher-Smith intends to pursue enhanced customer segmentation to further increase salesforce effectiveness in 2026 with investments in key commercial functions and patient access to increase salesforce effectiveness.
Recent Investor Conference
Bora will host an English online earnings call at 9:30 p.m. Taiwan time on Mar. 12th, 2026, followed by an investor conference hosted by Taishin Securities at the Regent Taipei at 2:00 p.m. on Mar. 19th, 2026. Both events will cover the Company’s 2025 financial and business results and 2026 outlook.
English Online Earnings Presentation Link: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5255333/bora-pharmaceuticals-otcqx-boray-twse-6472
Bora will participate in 2026 Jefferies Asia Forum in March in Hong Kong and an East coast NDR in NYC and Boston. For 1:1 meetings with management, please contact your Jefferies and Sinopac representative.
Bora 2026 Earnings Schedule
Q1 2026: Expected in the 2nd week of May 2026
Q2 2026: Expected in the 2nd week of Aug 2026
Q3 2026: Expected in the 2nd week of Nov 2026
Q4 2026: Expected in the 2nd week of Mar 2027
Hashtag: #Bora
The issuer is solely responsible for the content of this announcement.
About Bora
Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients’ quality of life.
By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success “certain,” Bora sets new standards in the pharmaceutical and CDMO industries.
For more, please visit:
https://www.bora-corp.com
https://www.boracdmo.com
Disclaimer:
This document and the accompanying information may contain forward-looking statements. All statements regarding the company’s future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company’s control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.
For much of the past century, urban development followed a relatively straightforward equation: build housing, expand infrastructure and accommodate population growth. This formula is now showing its limitations. As climate risk intensifies, biodiversity declines and cities compete not only for investment but also for talent, developers around the world are now forced to redefine the very nature and purpose of what they build.
From the Gulf to Singapore, and from Scandinavia to Southeast Asia, large-scale urban projects are evolving into integrated ecosystems where mobility, green infrastructure, education, healthcare, digital services and environmental restoration are planned together. The industry paradigm has shifted from constructing buildings to designing places capable of sustaining both economic growth and quality of life over generations.
Vinhomes has initiated a comprehensive repositioning to navigate this global transition.
Known as Vietnam’s largest residential developer, the company is increasingly recognized not merely as a builder of housing projects, but as a creator of large-scale lifestyle ecosystems, communities where urban planning, technology, ecology and public services are conceived as parts of the same system.
When Nature Becomes Urban Infrastructure
For decades, environmental considerations were often introduced after a city’s masterplan had already been completed.
The emerging model reverses that sequence. Across many of its recent developments, Vinhomes operates on the principle that natural systems should become the starting point of planning. Hydrology, coastal conditions, biodiversity and existing vegetation are treated as design inputs that shape the urban layout from the earliest stages.
This philosophy marks a notable departure from conventional large-scale development, particularly in rapidly urbanising markets where natural landscapes have frequently given way to intensive construction.
With more than 30 developments across Vietnam and a land bank equivalent to roughly two-thirds the size of Singapore, Vinhomes has the unusual opportunity to test this planning approach at a metropolitan scale.
Rather than replicating identical urban formulas, each project is designed around the ecological characteristics of its location.
The company maintains that the long-term success of a city should ultimately be measured not by how much has been built, but by whether natural ecosystems continue to thrive decades after residents have moved in. That perspective aligns with an increasingly influential school of urban planning in which green infrastructure is viewed as essential public infrastructure.
Factors Compelling Cities Toward Regeneration
Environmental, Social and Governance (ESG) frameworks have become standard across global investment. Urban planners, however, are beginning to question whether sustainability alone is sufficient.
Maintaining today’s environmental conditions may no longer be enough if tomorrow’s cities must also respond to rising temperatures, sea-level change and growing demographic pressures.
Vinhomes’ strategic response is crystallized in its ESG++, a framework that extends beyond conventional ESG principles by introducing two additional objectives: Regeneration and resilience.
The distinction is subtle but important.
Regeneration implies restoring ecological systems rather than simply reducing environmental impact. Resilience focuses on designing cities capable of adapting to changing climatic, technological and social conditions over many decades.
Projects such as Vinhomes Green Paradise Can Gio and Vinhomes Global Gates Ha Long are intended to demonstrate how these concepts can be incorporated into large-scale urban planning, combining renewable energy, smart infrastructure and ecological restoration within a single development model.
This shift highlights a growing global consensus: the success of next-generation cities will ultimately be measured by their ability to adapt to increasingly complex environmental challenges.
Vietnam’s Urban Story Is Becoming Part of a Global Conversation
For many international audiences, Vietnam remains associated primarily with its cultural heritage and natural landscapes. Urban development may become an equally important part of that story.
Rapid urbanisation, expanding infrastructure investment and a national commitment to achieve net-zero emissions by 2050 have created conditions in which entirely new urban models can be planned without many of the legacy constraints facing older cities.
This developmental opportunity is capturing increasing global interest.
Commenting on Vinhomes Green Paradise’s participation in the global 7 Wonders of Future Cities initiative, Jean-Paul de la Fuente, Director of the New7Wonders Organisation, described Vietnam as undergoing a “transformative step change” in its national identity and global positioning. He pointed to the country’s progress in reducing the carbon footprint of urban mobility as an example of coordinated action between government and the private sector that offers valuable insights extending beyond Southeast Asia.
For Vinhomes, participation in international platforms such as 7 Wonders of Future Cities is therefore less about showcasing a single project than about contributing to a broader discussion on how rapidly developing economies might approach urban growth differently. The company’s evolution mirrors a wider shift taking place across the global property sector.
Increasingly, the core value proposition for developers is no longer anchored in how many buildings they can deliver. Instead, it centers on whether they can create cities that remain economically competitive, environmentally resilient and socially relevant long after construction has ended.
Hashtag: #Vinhomes
https://vinhomes.vn/enThe issuer is solely responsible for the content of this announcement.
CUHK’s Academic Excellence and Global Research Impact
CUHK’s academic rigour is further recognised in the 2026–27 Best Global Universities Rankings by U.S. News & World Report, where it ranks 28th globally and 5th in Asia, remaining Hong Kong’s top university for the fourth consecutive year. The University features 15 subjects in the global top 50, including five in the top 10, such as Education and Educational Research (#1), Gastroenterology and Hepatology (#2), Computer Science (#7), and Arts and Humanities and Artificial Intelligence (both ranked #9).
CUHK: Where Bold Ideas Become Impactful Research
CUHK provides an exceptional environment for impactful research, supported by approximately 300 research institutes and centres, alongside four state key laboratories approved by the Ministry of Science and Technology of China. Reflecting on the academic environment, Zhamilya Zhirenova, a PhD student in Biomedical Science from Kazakhstan, has deepened her expertise through her involvement with the Centre for Neuromusculoskeletal Restorative Medicine (CNRM), an InnoHK research centre CUHK established with Sweden’s Karolinska Institutet.
Unlike traditional research pathways, where students are often confined to a single university laboratory, Zhamilya gained extensive experience at Hong Kong Science Park, a dynamic setting that closely resembles industry. “It feels more like an industrial company,” she reflected, “and that experience has been invaluable.” For researchers with ambitions beyond academia, such early exposure to the pace and expectations of the biotech industry provides a distinct advantage.
Nurturing the Next Generation of Scientific Innovators
Many of CUHK’s scholars are globally renowned experts who have made significant breakthroughs in their respective fields. These experts provide valuable mentorship, cultivating an intellectually stimulating environment for innovative research.
At the Centre for Novostics, an InnoHK research centre dedicated to advancing molecular diagnostics, Yasine Malki, a Chemical Pathology PhD student from Hong Kong, highlighted mentorship as a defining aspect of his experience at CUHK. Benefiting from the mentorship of Professor Dennis Lo, CUHK’s Vice-Chancellor and President, and a pioneer in molecular diagnostics, Yasine collaborates with specialists in molecular technologies, bioinformatics, and clinician-scientists, exemplifying CUHK’s dynamic, multidisciplinary approach to medical science.
Through the latest global rankings, CUHK continues to demonstrate the impact of its research and scholarship. The University offers robust financial support to attract top-tier global talent, such as the Hong Kong PhD Fellowship Scheme (HKPFS) for the 2027–28 intake, which provides over HK$1.81 million (approximately US$232,420) in funding. Applications open on 1 September 2026.
Hashtag: #CUHK
The issuer is solely responsible for the content of this announcement.
About CUHK
Founded in 1963, The Chinese University of Hong Kong (CUHK) is a leading comprehensive research university with a global reputation and world-leading rankings. Located in the heart of Asia, CUHK has a vision and a mission to combine tradition with modernity, and to bring together China and the West. The University has eight faculties: Arts, Business Administration, Education, Engineering, Law, Medicine, Science, and Social Science. Together with the Graduate School, the University offers over 300 undergraduate and postgraduate programmes. All faculties are actively engaged in research in a wide range of disciplines, with an array of research institutes and research centres specialising in interdisciplinary research of the highest quality.
Media OutReach
HKDL’s Immersive Interactive Experiences Win Guests’ Hearts Lucky Nugget Spin at Grizzly Gulch Surpasses 30,000 Participations
Immersive experiences fuel collectible merchandise craze and extend magical memories
HONG KONG SAR – Media OutReach Newswire – 11 July 2026 – In tune with the growing popularity of experiential travel and guests’ desire for participation and immersive experiences throughout their journeys, Hong Kong Disneyland Resort (HKDL) has been integrating retail with storytelling at the park through an endless flow of innovative interactive experiences and distinctive merchandise offerings. Emotional connections with guests are strengthened as merchandise is transformed into meaningful souvenirs interwoven with their Disney memories.
Launched in April this year at Grizzly Gulch, the Chip ‘n’ Dale Lucky Nugget Spin has recorded more than 30,000 participations as of the end of June, becoming one of the park’s most popular activities. Combining storytelling, live interactions, and surprises, the experience has been warmly received by guests and has further enhanced the atmosphere throughout the land.
David Koo, director of merchandise at Hong Kong Disneyland Resort, shared: ‘Today’s guests are looking for more than products; they want keepsakes that capture the stories and memories of their visit. Through interactive experiences, we hope to make merchandise a natural extension of the Disney park journey. Whether it is a plush toy, a pin or an accessory, the true value lies not only in the item itself, but in the magical moments and personal memories it represents.’
David Koo, director of merchandise at Hong Kong Disneyland Resort, is pictured in the center
This story- and interaction-driven strategy has been incorporated into various guest experiences across the resort. For example, in an engaging experience at the Popcorn Pop-Up Shop on Main Street, U.S.A., guests can reach into a giant popcorn bucket-themed installation to catch a “popcorn” and reveal the hidden Pixar pals plushie together with Disney cast members on the spot. Meanwhile, the Snow White Grotto, located beside the Castle of Magical Dreams, has introduced a new “Lock of Dreams” experience, offering guests a sense of ceremony and a souvenir to cherish.
Disney’s Classic Pin Trading Tradition Extends the Magic Beyond the Visit
Disney’s iconic Pin Trading tradition has long been an important part of how guests explore the park and connect with others. Reopened in June, Main Street Collectibles now features dedicated pin display areas designed to celebrate and elevate this beloved tradition. Guests can discover unexpected treasures while searching for favorite designs as they trade pins with Disney cast members and fellow collectors. More than just an addition to a collection, each pin carries unique memories and extends the guest journey.
More Than 3.5 Million 20th Anniversary Merchandise Items Snapped up
New Pixar and Marvel Experiences on the Way
Merchandise sales grew continuously during Hong Kong Disneyland’s 20th anniversary celebrations, which attracted a large number of local, mainland, and international visitors and concluded with fanfare in June. Since late June last year, the resort has sold more than 3.5 million 20th Anniversary-themed merchandise. Among them, about 600,000 units of the SouvenEARS collection have been snapped up. Meanwhile, the blind-box series inspired by attractions and themed lands achieved sales of more than 500,000 units during fiscal year 2025, demonstrating the continued popularity of merchandise with strong storytelling elements and collectible appeal.
Looking ahead, HKDL will continue to enrich the guest experience across the resort. New Pixar-themed and Marvel-themed experiences will be introduced, further expanding both entertainment and retail offerings. Through ongoing innovation, HKDL remains committed to meeting guests’ demand for more immersive experiences, enhancing its appeal to local, mainland, and international visitors, and strengthening its position as a leading travel destination in the region.
Hashtag: #HongKongDisneylandResort
The issuer is solely responsible for the content of this announcement.
